Reducing addiction, promoting competition FDA priorities for 2018
The Food and Drug Administration today announced four priority areas for additional policy activity in 2018: reducing addiction to opioid drugs and cigarettes; promoting innovation and competition; empowering consumers to make informed decisions; and strengthening the FDA workforce. Specific policy efforts include new steps to support and streamline development and approval of treatments that address addiction; reducing burdens for creating and approving generic drugs; and extending new hiring and pay authorities to recruit and retain FDA staff.
Related News Articles
Headline
The Food and Drug Administration July 31 announced that it is requiring safety label changes to all opioid pain medications to further emphasize and explain…
Headline
The Senate Appropriations Committee July 31 advanced the fiscal year 2026 appropriations bill for the Departments of Labor, Health and Human Services,…
Headline
The U.S. Department of Health and Human Services July 10 rescinded a policy that extended certain federal public benefits to immigrants lacking permanent legal…
Headline
Jon Ulven, Ph.D., behavioral health psychologist and chair of adult psychology at Sanford Health, details the fragile behavioral health landscape in rural…
Headline
The Centers for Medicare & Medicaid Services June 27 announced the rollout of a 6-year technology-enabled prior authorization program pilot. Through…
Headline
Kevin McEwan, DNP, R.N., chief nursing officer at Madison Memorial Hospital, shares how Medicaid provides vital behavioral health and maternal and child care…